Bacterial vaginosis in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Microbiology
• Public Health

Background:

• Bacterial vaginosis (BV) is a common vaginal condition characterized by an imbalance of bacteria, replacing beneficial Lactobacillus species with high concentrations of anaerobes.
• BV is the leading cause of vaginal discharge and malodor, affecting 10-41% of women, with many remaining asymptomatic.
• Emerging evidence links BV to increased maternal and fetal morbidity, including spontaneous abortion, preterm labor, and postpartum infections.

Purpose of the Study:

• To highlight the association between bacterial vaginosis and adverse pregnancy outcomes.
• To emphasize the importance of screening and antimicrobial treatment protocols for BV in pregnant women.
• To advocate for the adoption of new, low-cost point-of-care diagnostic tools for BV screening.

Main Methods:

• Review of clinical trials and evidence linking BV to maternal and fetal morbidity.
• Discussion of current screening and treatment guidelines, including CDC-P recommendations.
• Identification of patient subgroups who would most benefit from "screen and treat" approaches.

Main Results:

• Clinical trials show significant reductions in adverse pregnancy events through screening and antimicrobial treatment.
• New point-of-care diagnostic tools facilitate rapid BV screening, enabling timely intervention.
• Screening and treatment are associated with preventing preterm birth and its complications.

Conclusions:

• All pregnant women should be screened for BV early in pregnancy and treated with CDC-P recommended oral regimens.
• A "test of cure" 1 month post-treatment is recommended for all treated women.
• Specific high-risk groups, including those with prior preterm birth or low BMI, benefit significantly from BV screening and treatment.